Ixazomib is primarily used in combination with other drugs such as lenalidomide and dexamethasone in the treatment of multiple myeloma. It is indicated for patients who have received at least one prior therapy. The combination therapy has been shown to improve progression-free survival, offering a significant benefit over traditional therapies.
